Full Press Release Details
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
To access the live webcast of the fireside chat, please visit the Events and Presentations page within the Ardelyx website atir.ardelyx.com. A replay of the webcast will be available following the event.
About Ardelyx, Inc.Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with partners to develop and commercialize our products outside of the United States. For more information, please visithttps://ardelyx.com/and connect with us onX (formerly known as Twitter), LinkedInandFacebook.